Yahoo
NasdaqGM - Nasdaq Real Time Price USD

Vericel Corporation (VCEL)

39.56 -1.39 (-3.39%)
As of 3:04:25 PM EDT. Market Open.
Trade Vericel on Coinbase
Chart Range Bar
Loading chart for VCEL
  • Previous Close 40.95
  • Open 40.48
  • Bid 39.62 x 100
  • Ask 52.78 x 100
  • Day's Range 39.34 - 40.88
  • 52 Week Range 28.95 - 49.32
  • Volume 237,515
  • Avg. Volume 579,746
  • Market Cap (intraday) 2.026B
  • Beta (5Y Monthly) 1.07
  • PE Ratio (TTM) 82.42
  • EPS (TTM) 0.48
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 60.57

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.

www.vcel.com

398

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 8/31/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

VCEL
9.86%
S&P 500 (^GSPC)
12.13%

1-Year Return

VCEL
8.80%
S&P 500 (^GSPC)
18.81%

3-Year Return

VCEL
20.50%
S&P 500 (^GSPC)
70.28%

5-Year Return

VCEL
26.97%
S&P 500 (^GSPC)
69.71%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 77.46M
Earnings 2.21M
Profit Margin 2.85%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
20M
40M
60M
80M
0.0%
10.0%
20.0%

Analyst Insights

View More

Analyst Price Targets

55.00
60.57 Average
39.56 Current
72.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 7/31/2026
Analyst TD Cowen
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 55 -> 58

Statistics

View More

Valuation Measures

Annual
As of 8/27/2026
  • Market Cap

    2.11B

  • Enterprise Value

    2.04B

  • Trailing P/E

    85.79

  • Forward P/E

    86.96

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    7.06

  • Price/Book (mrq)

    5.70

  • Enterprise Value/Revenue

    6.66

  • Enterprise Value/EBITDA

    52.77

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    7.91%

  • Return on Assets (ttm)

    2.43%

  • Return on Equity (ttm)

    7.16%

  • Revenue (ttm)

    306.3M

  • Net Income Avi to Common (ttm)

    24.22M

  • Diluted EPS (ttm)

    0.48

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    162.46M

  • Total Debt/Equity (mrq)

    25.17%

  • Levered Free Cash Flow (ttm)

    55.54M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

39.56 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

Research Reports

View More
  • Lowering target price to $45.00

    VERICEL CORP has an Investment Rating of HOLD; a target price of $45.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.

    Rating
    Price Target
  • Lowering target price to $46.00

    VERICEL CORP has an Investment Rating of HOLD; a target price of $46.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.

    Rating
    Price Target
  • Lowering target price to $47.00

    VERICEL CORP has an Investment Rating of HOLD; a target price of $47.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.

    Rating
    Price Target
  • What does Argus have to say about VCEL?

    VERICEL CORP has an Investment Rating of HOLD; a target price of $49.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.

    Rating
    Price Target

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: